Trial · NCT02357810
Participant flow20
How many started, completed or left each group, period by period.
1 to 20 of 20
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Registered and Started Treatment | STARTED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 178 | |
| Registered and Started Treatment | Signed Consent | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 178 | |
| Registered and Started Treatment | Registered to Study | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 152 | |
| Registered and Started Treatment | Initiated Treatment on Study | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 151 | |
| Registered and Started Treatment | COMPLETED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 151 | |
| Registered and Started Treatment | NOT COMPLETED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 27 | |
| Reached 12 Weeks Response | STARTED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 151 | |
| Reached 12 Weeks Response | Completed 4 Weeks/1 Cycle | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 151 | |
| Reached 12 Weeks Response | Reached 6 Week Response | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 129 | |
| Reached 12 Weeks Response | Reached 12 Weeks/3 Cycles | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 95 | |
| Reached 12 Weeks Response | COMPLETED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 95 | |
| Reached 12 Weeks Response | NOT COMPLETED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 56 | |
| 12 Week Response and Further Treatment | STARTED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 95 | |
| 12 Week Response and Further Treatment | Assessed for 12 Week Response | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 95 | |
| 12 Week Response and Further Treatment | Went on to be Treated After Response | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 73 | |
| 12 Week Response and Further Treatment | COMPLETED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 73 | |
| 12 Week Response and Further Treatment | NOT COMPLETED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 22 | |
| Follow-up at Treatment Discontinuation | STARTED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 151 | |
| Follow-up at Treatment Discontinuation | COMPLETED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 144 | |
| Follow-up at Treatment Discontinuation | NOT COMPLETED | Treatment (Pazopanib Hydrochloride, Topotecan Hydrochloride) | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02357810/flow